Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 6, 2026Nature CommunicationsOpen Access

Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity

View Full Paper
Ask AI
Bookmark
Share

Authors

DGDiego GilioliSFSimona FuscoTTTeresa Tavella

Discussion

Loading...

Member takes

Overview

Preclinical study shows that therapy-induced senescence boosts T-cell responses in acute myeloid leukemia through reduced PRC2 activity, suggesting strategies to improve immunotherapy sensitivity.

Key Points

  • To elucidate the immunological consequences of chemotherapy-induced senescence in acute myeloid leukemia and determine the molecular mechanisms controlling anti-leukemic immune activation.
  • Treated primary therapy-naïve acute myeloid leukemia cells ex vivo with chemotherapy to trigger senescence and analyzed human leukocyte antigen (HLA) expression and peptide presentation.
  • Evaluated autologous CD4+ and CD8+ T-cell responses and sensitivity to immune checkpoint blockade ex vivo and in patient-derived xenograft models.
  • Investigated the mechanistic role of Polycomb Repressive Complex 2 (PRC2) and EZH2 activity using pharmacological inhibition in non-senescent leukemia cells.
  • Therapy-induced senescence elevated interferon signaling and upregulated HLA class I and II molecules, conferring antigen-presenting cell-like characteristics on acute myeloid leukemia cells.
  • Senescent leukemia cells enhanced autologous CD4+ and CD8+ T-cell responses both ex vivo and in xenograft models, successfully restoring sensitivity to immune checkpoint blockade.
  • Loss of PRC2 activity drove senescence-associated immunogenicity, and direct PRC2 inhibition restored HLA expression and enabled T-cell activation in non-senescent leukemia cells.

Cite This Study

Gilioli et al. (2026) studied this question.

synapsesocial.com/papers/6a9d1ee128139818eab220cdhttps://doi.org/10.1038/s41467-026-76853-1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapy-induced senescence reprograms non-M3 AML into a drug-exploitable APL-like state2025
  2. 2Therapy-Induced Cellular Senescence in Non-Hodgkin Lymphomas, with Emphasis on Aggressive B-Cell Subtypes: Molecular Mechanisms and Emerging Drug Targets2026
  3. 3Abstract LB150: Senescence as an immune tolerance breaker: Inhibitors of mitotic kinases TTK (Mps1) and AURKA induce pro-immunogenic senescence that primes the tumor microenvironment for immunotherapy via cGAS-STING signaling2026
  4. 4Abstract 6475: Myeloma cells with therapy-induced senescence-like phenotype have increased resistance to killing by T cell directed therapies2026
  5. 5Prognostic significance of therapy-induced senescence and SASP dynamics in acute myeloid leukemia: a retrospective cohort study2026